Loading…
Employees: 4,218
Size Aarti Pharmalabs (AARTIPHARM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $892M, the 630th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹929.10 on 6 Nov 2026.
Performance Over six months the shares gained 19.5%, against -14.9% for the median peer and 0.0% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 13.4% over the last twelve months (peer median +1.3%); the operating margin is 17.7% (peer median 3.6%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 4.4× (9th cheapest of 18).
Capital Return on invested capital runs 3.6 points below its cost of capital (12.7% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹21.6B | ₹17.9B | ₹20.9B | ₹18.2B | ₹19.4B |
| Revenue growth | — | -14% | +15% | -6% | — |
| Gross profit | ₹8.59B | ₹4.93B | ₹5.94B | ₹3.93B | ₹4.07B |
| EBITDA | ₹5.00B | ₹3.81B | ₹4.42B | ₹3.55B | ₹3.36B |
| Net income | ₹2.57B | ₹1.75B | ₹2.72B | ₹2.17B | ₹1.93B |
| Free cash flow | n/a | -₹1.84B | -₹893M | ₹466M | ₹1.28B |
| Capital expenditure | n/a | ₹4.48B | ₹4.44B | ₹1.99B | ₹1.20B |
| Total debt | ₹8.97B | ₹7.54B | ₹4.13B | ₹2.85B | ₹2.15B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AARTIPHARM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.5% | -6.6% | 6th highest of 20 |
| 6-month return | +19.5% | -14.9% | 2nd highest of 20 |
| Distance from 52-week high | -7.3% | -35.5% | highest of 21 |
| Revenue growth (TTM) | +13.4% | +1.3% | 4th highest of 19 |
| Operating margin | 17.7% | 3.6% | 3rd highest of 19 |
| EV / Sales | 4.3× | 4.4× | 9th cheapest of 18 |
| ROIC minus cost of capital | -3.6 pp | -2.2 pp | 7th lowest of 18 |
| EV / EBITDA | 18.6× | 17.8× | 4th most expensive of 8 |
| Net debt / EBITDA | 1.8× | 1.8× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | 4.3× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | 7.1× | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 6.1× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | 57.5× | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | 2.9× | 16.2% | -0.2% |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | 5.9× | -1.2% | -39.5% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | 5.2× | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 0.7× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 2.1× | 2.5% | +12.4% |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 3.6× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 1.9× | 4.8% | +22.5% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | 15.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 4.4× | 33.2% | +4.2% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 0.9× | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 5.1× | 16.2% | +27.3% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 4.7× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | 1.0× | -6.8% | -0.7% |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 1.2× | -10.5% | +1.9% |